Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | PPM1B | O75688 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639450 | 1.00 | ALDH1A1 (0.33) | ALDH1A1NPSR1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL3744024 | 1.00 | ALDH1A1 (0.33) | ALDH1A1NPSR1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL3641631 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2PPM1BPTPN1 | |
| SCHEMBL3754080 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2PPM1BPTPN1 | |
| SCHEMBL3747168 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2PPM1BPTPN1 | |
| SCHEMBL3642215 | 0.79 | CYP1A2 (0.35) | CYP1A2EPHX1 | |
| SCHEMBL3748787 | 0.79 | EPHX1 (0.33) | CYP1A2EPHX1 | |
| SCHEMBL3642324 | 0.75 | ATM (0.37) | NPSR1MAPTSMN1; SMN2CYP1A2HIF1A | |
| SCHEMBL3643311 | 0.71 | HSD17B10 (0.33) | CYP1A2 | |
| SCHEMBL3750204 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167621-B1 | ORGANIC COMPOUNDS AS ODORANTS | GIVAUDAN SA (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-9012391-B2 | Organic compounds | GIVAUDAN SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-20100292128-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292128-A1 | Organic Compounds | TRPA1, FASN, OR10J3 | ALDH1A1 99/4885NPSR1 3243/4885MAPT 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.